Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA

Watchlist Manager
Sun Pharmaceutical Industries Ltd Logo
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Watchlist
Price: 1 795.3 INR 0.86% Market Closed
Market Cap: 4.3T INR
Have any thoughts about
Sun Pharmaceutical Industries Ltd?
Write Note

Sun Pharmaceutical Industries Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sun Pharmaceutical Industries Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash from Operating Activities
â‚ą127.2B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash from Operating Activities
â‚ą45.4B
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash from Operating Activities
â‚ą45B
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Cash from Operating Activities
â‚ą32.3B
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash from Operating Activities
â‚ą34.1B
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Cash from Operating Activities
â‚ą21.5B
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sun Pharmaceutical Industries Ltd
Glance View

Market Cap
4.3T INR
Industry
Pharmaceuticals

Sun Pharmaceutical Industries Ltd. is a leading global pharmaceutical company based in India, renowned for its commitment to producing high-quality generic and specialty medicines. Founded in 1983, Sun Pharma has evolved into one of the largest pharmaceutical companies in India and the fifth largest globally in the generic market. With a robust portfolio that encompasses various therapeutic areas, including cardiology, psychiatry, neurology, and oncology, the company has built a solid reputation for innovation and reliability. A strong emphasis on research and development drives Sun Pharma’s growth, helping it to continuously expand its product offerings and tap into new markets, as evidenced by its strategic acquisitions and partnerships over the years. For investors, Sun Pharmaceutical presents a compelling opportunity, underpinned by its solid financial performance and a forward-looking strategic vision. The company's extensive presence in over 150 countries combined with a diverse portfolio fuels its competitive edge in the global pharmaceutical landscape. With a solid track record of profitability and a commitment to enhancing shareholder value, Sun Pharma is well-positioned to capture growth in emerging markets and capitalize on advancements in biologics and complex generics. Moreover, the company’s focus on sustainability and ethical practices resonates in an increasingly socially conscious investment environment, making it an appealing prospect for investors looking to diversify their portfolios while supporting a responsible industry leader.

SUNPHARMA Intrinsic Value
1 046.73 INR
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Sun Pharmaceutical Industries Ltd's Cash from Operating Activities?
Cash from Operating Activities
127.2B INR

Based on the financial report for Sep 30, 2024, Sun Pharmaceutical Industries Ltd's Cash from Operating Activities amounts to 127.2B INR.

What is Sun Pharmaceutical Industries Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
16%

Over the last year, the Cash from Operating Activities growth was 4%. The average annual Cash from Operating Activities growth rates for Sun Pharmaceutical Industries Ltd have been 16% over the past three years .

Back to Top